Form 4: Revolution Medicines Director, Alexis Borisy, Reports Acquisition of Shares and Stock Options

Director Alexis Borisy reports acquiring 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.

Summary

• On June 20, 2024, Alexis Borisy, a director of Revolution Medicines, Inc., reported acquiring 4,800 shares of common stock at $0 and 16,700 stock options with an exercise price of $37.54.
• Following these transactions, Borisy beneficially owns 2,336,294 shares of common stock, including 4,800 Restricted Stock Units, and 16,700 stock options.
• The stock options vest fully on the earlier of June 20, 2025, or immediately before the Annual Meeting following the grant date, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing transactions by a company director. The acquisition of shares and options could be seen as a positive signal, but it's not overtly bullish.

Positives

• The acquisition of shares and stock options by a director could be interpreted positively, signaling confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of stock options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign of confidence in the company's prospects.

Key Dates